HC Wainwright Issues Pessimistic Outlook for ORKA Earnings

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Oruka Therapeutics in a research note issued to investors on Monday, April 28th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.44) per share for the quarter, down from their prior estimate of ($0.41). HC Wainwright has a "Buy" rating and a $45.00 price target on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Oruka Therapeutics' Q2 2025 earnings at ($0.49) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($2.08) EPS.

Several other analysts have also issued reports on ORKA. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a report on Friday, March 7th. Wolfe Research began coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $39.86.

Oruka Therapeutics Price Performance

NASDAQ:ORKA traded down $0.19 on Thursday, hitting $9.80. 32,042 shares of the company's stock were exchanged, compared to its average volume of 283,022. The company has a market cap of $366.73 million, a P/E ratio of -1.56 and a beta of 0.25. The firm has a 50-day moving average price of $9.98 and a 200-day moving average price of $15.93. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $53.88.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.19.

Insider Activity at Oruka Therapeutics

In other news, major shareholder Venrock Healthcare Capital Par acquired 88,794 shares of Oruka Therapeutics stock in a transaction dated Friday, February 14th. The stock was bought at an average price of $11.44 per share, for a total transaction of $1,015,803.36. Following the completion of the acquisition, the insider now directly owns 4,148,428 shares in the company, valued at approximately $47,458,016.32. The trade was a 2.19 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 98,339 shares of company stock worth $1,128,456. Company insiders own 22.67% of the company's stock.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors have recently modified their holdings of the business. FMR LLC raised its stake in Oruka Therapeutics by 17.7% in the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock worth $106,883,000 after purchasing an additional 830,000 shares in the last quarter. Fairmount Funds Management LLC raised its position in shares of Oruka Therapeutics by 5.0% in the fourth quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock valued at $65,382,000 after buying an additional 160,000 shares in the last quarter. VR Adviser LLC boosted its stake in shares of Oruka Therapeutics by 6.5% in the fourth quarter. VR Adviser LLC now owns 3,285,620 shares of the company's stock valued at $63,708,000 after buying an additional 200,000 shares during the period. RTW Investments LP grew its position in Oruka Therapeutics by 5.1% during the fourth quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock worth $37,726,000 after buying an additional 95,001 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Oruka Therapeutics by 4,161.2% during the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after buying an additional 1,572,853 shares in the last quarter. Institutional investors own 56.44% of the company's stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.